Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» 3 Reasons Why Johnson & Johnson Stock Could Rebound After a Bad Start in 2023
3 Reasons Why Johnson & Johnson Stock Could Rebound After a Bad Start in 2023
3 Reasons Why Johnson & Johnson Stock Could Rebound After a Bad Start in 2023
Submitted by
admin
on January 25, 2023 - 10:28am
Source:
Motley Fool
News Tags:
JNJ
COVID-19
consumer health
foreign exchange rates
Headline:
3 Reasons Why Johnson & Johnson Stock Could Rebound After a Bad Start in 2023
snippet:
The negative impact associated with COVID-19 should become less of an issue for J&J this year.
Foreign-exchange headwinds seem likely to subside somewhat in 2023, potentially boosting J&J's sales.
J&J's upcoming spinoff of its consumer health unit could provide a catalyst.
Do Not Allow Advertisers to Use My Personal information